Last 25 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 208.08 | 56.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.17 | 6.99 | 7.56 | 5.75 | 5.38 | 4.65 | 3.21 | 2.86 | 4.02 | 8.39 | 6.04 | 6.22 | 6.72 | 4.92 | 5.06 | 1.85 | 6.99 | 5.49 | 3.03 | 4.23 | 8.17 |
| — | +50.3% | +135.6% | +101.3% | +33.8% | -44.6% | -46.9% | -54.0% | -40.2% | +70.7% | +19.4% | +235.4% | -3.9% | -10.4% | +66.7% | -56.2% | -14.4% | +27.1% | +100.8% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 67.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -931.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -911.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.7% | -25.3% | -24.1% | -21.9% | -18.2% | -18.5% | -15.3% | -9.3% | -10.0% | -15.1% | -9.9% | -12.5% | -22.8% | -15.2% | -13.5% | -25.6% | -35.5% | -21.7% | -11.6% | -16.7% | -21.7% |
| — | -36.6% | -58.1% | -135.8% | -81.1% | -22.5% | -54.2% | +25.5% | +56.0% | +0.7% | +26.8% | +51.4% | +35.9% | +29.9% | -16.5% | -53.0% | -63.5% | -153.5% | -211.2% | — | — | |
| ROA | -43.1% | -18.8% | -19.0% | -17.8% | -14.5% | -14.7% | -12.9% | -8.2% | -8.5% | -12.2% | -8.3% | -9.5% | -14.6% | -10.8% | -10.0% | -17.6% | -24.7% | -17.6% | -9.5% | -13.7% | -19.3% |
| — | -28.1% | -47.3% | -118.5% | -71.6% | -20.3% | -56.0% | +14.4% | +42.0% | -12.3% | +17.1% | +45.9% | +40.8% | +38.5% | -5.2% | -28.4% | -28.2% | -118.5% | -105.9% | -55.0% | +75.5% | |
| ROIC | -54.6% | -18.2% | -18.9% | -23.8% | -19.0% | -13.8% | -11.7% | -8.0% | -8.6% | -11.1% | -8.1% | -10.4% | -17.2% | -12.4% | -17.6% | -40.5% | -33.1% | -22.2% | -19.0% | -83.6% | — |
| — | -32.5% | -61.8% | -198.3% | -121.1% | -23.8% | -44.3% | +23.4% | +50.2% | +10.6% | +54.0% | +74.3% | +48.0% | +44.0% | +7.6% | +51.5% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.23 | 0.18 | 0.15 | 0.13 | 0.19 | 0.17 | 0.10 | 0.09 | 0.19 | 0.16 | 0.15 | 0.53 | 0.24 | 0.21 | 0.19 | 0.41 | 0.11 | 0.10 | 0.10 | 0.07 |
| — | +17.0% | +11.4% | +47.5% | +35.1% | +1.9% | +2.8% | -32.4% | -82.1% | -20.4% | -24.8% | -22.6% | +29.8% | +107.9% | +113.9% | +104.6% | +475.1% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.64 | 7.91 | 10.92 | 13.64 | 13.64 | 12.09 | 17.03 | 27.68 | 25.67 | 13.76 | 21.43 | 28.63 | 7.71 | 6.97 | 7.10 | 8.69 | 4.91 | 7.85 | 8.24 | 7.90 | 10.73 |
| — | -34.5% | -35.9% | -50.7% | -46.9% | -12.2% | -20.6% | -3.3% | +232.8% | +97.4% | +201.7% | +229.5% | +57.1% | -11.2% | -13.8% | +10.0% | -54.3% | -64.6% | -67.6% | -42.5% | -52.4% | |
| Quick Ratio | 13.64 | 7.78 | 10.92 | 13.64 | 13.64 | 12.09 | 17.03 | 27.68 | 25.67 | 13.76 | 21.43 | 28.63 | 7.71 | 6.97 | 7.10 | 8.69 | 4.91 | 7.85 | 8.24 | 7.90 | 10.73 |
| — | -35.6% | -35.9% | -50.7% | -46.9% | -12.2% | -20.6% | -3.3% | +232.8% | +97.4% | +201.7% | +229.5% | +57.1% | -11.2% | -13.8% | +10.0% | -54.3% | -64.6% | -67.6% | -42.5% | -52.4% | |
| Interest Coverage | -38.78 | -49.03 | -58.24 | -65.39 | -46.84 | -39.97 | -39.84 | -27.85 | -22.21 | -23.09 | -16.63 | -13.89 | -25.12 | -20.32 | -21.06 | -33.40 | -56.06 | -166.88 | -115.04 | -143.79 | -841.30 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VERA stock.
Vera Therapeutics, Inc.'s current P/E is -5.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vera Therapeutics, Inc.'s business trajectory between earnings reports.